Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate

Contraception

Volumn 84, Issue 2, 2011, Pages 122-127

  Viola, Alexandre S ^a,b   Castro, Sara ^a,b   Marchi, Nadia M ^a,b   Bahamondes, M Valeria ^a,b   Viola, Carolina F M ^a,b   Bahamondes, Luis ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b National Institute of Hormones and Women's Health   (Brazil)

Author keywords

Bone mineral density; Depot medroxyprogesterone acetate; Menopause

Indexed keywords

COPPER INTRAUTERINE DEVICE; MEDROXYPROGESTERONE ACETATE; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOREARM; GROUPS BY AGE; HORMONAL CONTRACEPTION; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; RADIUS; TREATMENT DURATION;

BONE DENSITY; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAUTERINE DEVICES, COPPER; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; POSTMENOPAUSE; PREGNANCY; RADIUS;

EID: 79960298846     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.11.007     Document Type: Article

References (33)

1. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety Contraception 68 2003 75 87 (Pubitemid 37101031)
2. Fraser I.S., and Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate Med J Aust 1 Suppl 1 1981 3 19
3. Kaunitz A.M. Current concepts regarding use of DMPA J Reprod Med 47 9 Suppl 2002 785 789
4. Bahamondes L., Trevisan M., and Andrade L. The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera Contraception 62 2000 23 27
5. Bagger Y.Z., Tanko L.B., and Alexandersen P. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study Bone 34 2004 728 735 (Pubitemid 38393810)
6. Renner R.M., Edelman A.B., and Kaunitz A.M. Depot medroxyprogesterone acetate contraceptive injections and skeletal health Womens Health (Lond Engl) 6 2010 339 342
7. Cromer B.A., Stager M., and Bonny A. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls J Adolesc Health 35 2004 434 441 (Pubitemid 39576013)
8. Scholes D., Lacroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women Contraception 69 2004 99 104 (Pubitemid 38167458)
9. Lara-Torre E., Edwards C.P., Perlman S., and Hertweek S.P. Bone mineral density in adolescent females using depot medroxyprogesterone acetate J Pediatr Adolesc Gynecol 17 2004 17 21 (Pubitemid 38315009)
10. d'Arcangues C. WHO statement on hormonal contraception and bone health Contraception 73 2006 443 444
11. United States Food and Drug Administration Black box warning on Depo-Provera contraceptive injection, November 17 2004
12. Duff G. Updated prescribing advice on the effect of Depo-Provera contraception on bones. HSS (MD) 39-2004. Available at: http://www.mhra.gov.uk/ home/idcplg?IdcService=GET-FILE&dDocName=con019478& RevisionSelectionMethod=Latest (MD) 39-2004, November, 19, 2004.
13. Kaunitz A.M. Depo-Provera's black box: time to reconsider? Contraception 72 2005 165 167 (Pubitemid 41133354)
14. Guilbert E.R., Brown J.P., and Kaunitz A.M. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health Contraception 79 2009 167 177
15. Lappe J.M., Stegman M.R., and Recker R.R. The impact of lifestyle fractures in female army recruits Osteoporos Int 12 1997 35 42 (Pubitemid 32236685)
16. Harel Z., Johnson C.C., and Gold M.A. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections Contraception 81 2010 281 291
17. Tolaymat L.L., and Kaunitz A.M. Use of hormonal contraception in adolescents: skeletal health issues Curr Opin Obstet Gynecol 21 2009 396 401
18. Walsh J.S., Eastell R., and Peel N.F. Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density Fertil Steril 93 2010 697 701
19. Rahman M., and Berenson A.B. Predictors of higher bone mineral density loss and use of depot medroxyprogesterone acetate Obstet Gynecol 115 2010 35 40
20. Cundy T., Cornish J., Roberts H., and Reid I.R. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception Am J Obstet Gynecol 186 2002 978 983
21. Cundy T., Cornish J., Evans M.C., Roberts H., and Reid I.R. Recovery of bone density in women who stop using medroxyprogesterone acetate BMJ 308 1994 247 248 (Pubitemid 24089097)
22. Orr-Walker B.J., Evans M.C., Ames R.W., Clearwater J.M., Cundy T., and Reid I.R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women Clin Endocrinol (Oxf) 49 1998 615 618 (Pubitemid 28529760)
23. Kaunitz A.M., Arias R., and McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use Contraception 77 2008 67 76
24. Sanches L., Marchi N.M., Castro S., Julianato C.T., Villarroel M., and Bahamondes L. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate Contraception 78 2008 365 369 Erratum in: Contraception. 2009;79:159-60
25. Tang O.S., Tang G., Yip P.S., and Li B. Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study Contraception 62 2000 161 164 (Pubitemid 32008602)
26. Berenson A.B., Breitkopf C.R., Grady J.J., Rickert V.I., and Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use Obstet Gynecol 103 2004 899 906 (Pubitemid 40458990)
27. Scholes D., LaCroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Injectable hormone contraception and bone density: results from a prospective study Epidemiology 13 2002 581 587
28. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ 312 1996 1254 1259 (Pubitemid 26147662)
29. Jones T., and Davie M.W. Bone mineral density at distal forearm can identify patients with osteoporosis at spine or femoral neck Br J Rheumatol 37 1998 539 543
30. Picard D., Brown J.P., and Rosenthall L. Ability of peripheral DXA measurement to diagnose osteoporosis as assessed by central DXA measurement J Clin Densitom 7 2004 111 118 (Pubitemid 38223472)
31. Harel Z., Wolter K., and Gold M.A. Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: a pilot study J Pediatr Adolesc Gynecol 23 2010 209 214
32. Beksinska M.E., Kleinschmidt I., Smit J.A., and Farley T.M. Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate Contraception 79 2009 345 349
33. Kaunitz A.M., Darney P.D., Ross D., Wolter K.D., and Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density Contraception 80 2009 7 17